Search company, investor...
Butterfly Network company logo

Butterfly Network

butterflynetwork.com

Founded Year

2011

Stage

Grant | IPO

Total Raised

$358.5M

Market Cap

0.62B

Stock Price

3.05

About Butterfly Network

Butterfly Network operates within diagnostic and therapeutic imaging with devices, deep learning, and the cloud. Butterfly Network operates at the intersection of engineering and medicine by bringing together computer science, physics, mechanical engineering, electrical engineering, and medicine. The company was founded in 2011 and is based in Guilford, Connecticut.

Headquarters Location

530 Old Whitfield Street

Guilford, Connecticut, 06437,

United States

Missing: Butterfly Network's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Butterfly Network's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Butterfly Network

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Butterfly Network is included in 10 Expert Collections, including Digital Health.

D

Digital Health

21,956 items

Startups recreating how healthcare is delivered

A

AI 100

200 items

A

Artificial Intelligence

9,442 items

This collection includes startups selling AI SaaS, using AI algorithms to develop their core products, and those developing hardware to support AI workloads.

D

Digital Health 150

150 items

2019's cohort of the most promising digital health startups transforming the healthcare industry

M

Medical Devices

12,088 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

C

Conference Exhibitors

5,302 items

Butterfly Network Patents

Butterfly Network has filed 1 patent.

The 3 most popular patent topics include:

  • Medical ultrasonography
  • Ultrasound
  • Acoustics
patents chart

Application Date

Grant Date

Title

Related Topics

Status

8/30/2018

10/25/2022

Medical ultrasonography, Medical equipment, Ultrasound, Medical physics, Medical equipment manufacturers

Grant

Application Date

8/30/2018

Grant Date

10/25/2022

Title

Related Topics

Medical ultrasonography, Medical equipment, Ultrasound, Medical physics, Medical equipment manufacturers

Status

Grant

Latest Butterfly Network News

Lifshitz Law PLLC Announces Investigations of Natera, Inc. (NASDAQ: NTRA), Butterfly Network, Inc. (NYSE: BFLY), Pulse Biosciences, Inc. (NASDAQ: PLSE), and SunPower Corporation (NASDAQ: SPWR)

Nov 20, 2022

Hewlett, New York, UNITED STATES NEW YORK, Nov. 19, 2022 (GLOBE NEWSWIRE) -- Natera, Inc. (NASDAQ: NTRA) Lifshitz Law PLLC announces that a class action complaint was filed on behalf of shareholders of Natera alleging that Defendants misrepresented and/or failed to disclose that: (i) the Company’s Panorama Non-Invasive Prenatal Test was not reliable and resulted in high rates of false positives; (ii) its Prospera test did not have superior precision compared to competing tests; (iii) as a result of Defendants’ false and misleading claims about Natera’s technology, the Company was exposed to substantial legal and regulatory risks; (iv) Natera relied upon deceptive sales and billing practices to drive its revenue growth; and (v) as a result of the foregoing, Defendants’ statements about the company’s business, operations, and prospects lacked a reasonable basis. If you are a Natera investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or email at info@jlclasslaw.com . Butterfly Network, Inc. (NYSE: BFLY) Lifshitz Law PLLC announces that a class action complaint was filed on behalf of shareholders of Butterfly Network alleging that the Company’s Proxy Statement in connection with its merger with Longview was negligently prepared, and as a result contained untrue statements of material fact or omitted to state other facts necessary to make the statements made not misleading. Additionally, the complaint alleges that Defendants made false and/or misleading statements and/or failed to disclose that: (i) Butterfly had overstated its post-Merger business and financial prospects; (ii) notwithstanding the ongoing COVID-19 pandemic, Butterfly’s financial projections failed to take into account the pandemic’s broad consequences, which included healthcare logistical challenges, and medical personnel fatigue; (iii) accordingly, Butterfly’s gross margin levels and revenue projections were less sustainable than the Company had represented; (iv) all the foregoing was reasonably likely to have a material negative impact on Butterfly’s business and financial condition; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times. If you are a Butterfly Network investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or email at info@jlclasslaw.com . Pulse Biosciences, Inc. (NASDAQ: PLSE) Lifshitz Law PLLC announces that a class action complaint was filed on behalf of shareholders of Pulse Biosciences alleging that Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (i) that the Company’s IDE study evaluating the use of the CellFX System to treat sebaceous hyperplasia lesions failed to meet its primary endpoints; (ii) that, as a result, there was a substantial risk that the FDA would reject Pulse’s 510(k) submission seeking to expand the label for the CellFX System to treat sebaceous hyperplasia lesions; and (iii) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. If you are a Pulse Biosciences investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or email at info@jlclasslaw.com . SunPower Corporation (NASDAQ: SPWR) Lifshitz Law PLLC announces that a class action complaint was filed on behalf of shareholders of SunPower alleging that Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (i) that certain connectors used by SunPower suffered from cracking issues; (ii) that, as a result, the Company was reasonably likely to incur costs to remediate the faulty connectors; (iii) that, as a result of the foregoing, SunPower’s financial results would be adversely impacted; and (iv) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. If you are a SunPower investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or email at info@jlclasslaw.com . ATTORNEY ADVERTISING.© 2022 Lifshitz Law PLLC. The law firm responsible for this advertisement is Lifshitz Law PLLC, 1190 Broadway, Hewlett, New York 11557, Tel: (516)493-9780. Prior results do not guarantee or predict a similar outcome with respect to any future matter. Contact:

Butterfly Network Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Butterfly Network Rank

Butterfly Network Frequently Asked Questions (FAQ)

  • When was Butterfly Network founded?

    Butterfly Network was founded in 2011.

  • Where is Butterfly Network's headquarters?

    Butterfly Network's headquarters is located at 530 Old Whitfield Street, Guilford.

  • What is Butterfly Network's latest funding round?

    Butterfly Network's latest funding round is Grant.

  • How much did Butterfly Network raise?

    Butterfly Network raised a total of $358.5M.

  • Who are the investors of Butterfly Network?

    Investors of Butterfly Network include Bill & Melinda Gates Foundation, Longview Acquisition, Paycheck Protection Program, Fidelity Investments, Jamie Dinan and 7 more.

  • Who are Butterfly Network's competitors?

    Competitors of Butterfly Network include Ibex Medical Analytics, Koios Medical, Cleerly, Lunit, Aidoc Medical, Pulsenmore, Pons, Viz.ai, Clarius Mobile Health, SenseTime and 31 more.

Compare Butterfly Network to Competitors

Caption Health Logo
Caption Health

Caption Health uses deep learning to help medical professionals in developing countries interpret ultrasounds so they can better treat heart disease. The company was founded in 2013 and is based in Brisbane, California.

Koios Medical Logo
Koios Medical

Koios Medical is a provider of software solutions for radiologists diagnosing cancer. Using AI algorithms trained on thousands of images combined with data from pathology results, Koios DS™ is decision support for healthcare diagnostics. Koios Medical was formerly known as Clearview Diagnostics. The company was founded in 2012 and is based in Chicago, Illinois.

A
Aidoc Medical

Aidoc finds and flags critical findings in medical images. By automatically prioritizing urgent, life-threatening conditions like intracranial hemorrhage and pulmonary embolism, Aidoc saves lives, improves patient care and cuts waiting time for the must urgent patients down to only a few minutes. The always-on AI integrates into a radiologist's workflow, reprioritizing cases without forcing radiologists to change the way they work. Aidoc was founded in 2016 and is based in Tel Aviv, Israel.

Ibex Medical Analytics Logo
Ibex Medical Analytics

Ibex Medical Analytics develops clinical decision support tools that help pathologists deliver metric-driven, objective and accurate diagnoses. It develops a diagnostic system that uses computer vision, machine learning, and electronic medical records to help confirm cancer diagnoses of tissue biopsies. The company was founded in 2016 and is based in Tel Aviv, Israel.

Ultrasight Logo
Ultrasight

Ultrasight develops an automated ultrasound solution that provides AI-based navigation, analysis, and diagnosis at the point of care.

Infervision Logo
Infervision

Infervision is a global high-tech enterprise in medical artificial intelligence, aiming to empower doctors with higher efficiency and benefit patients with better diagnosis, outcome, and lower cost. Infervision provides products and services to providers, and patients; with robust A.I. solutions fully integrated with the healthcare workflow to help diagnosing various diseases and conditions such as cerebral hemorrhage, lung cancer, bone fractures, emphysema, and more. Infervision also provides an AI-powered research platform for medical professionals with any research directions and needs.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.